Replicor a biopharmaceutical company targeting a cure for Chronic Hepatitis B patients will present updated human clinical trial data documenting a 4 to 6 log reduction in s-antigen and a long-term SVR in 80% of patients.
December 1, 2014 – Recently updated clinical trial data from Replicor’s Phase 2 trials will be presented at the Piper Jaffray Healthcare Conference Dec 3rd in New York City. Replicor’s Chief Scientific Officer Dr. Andrew Vaillant Ph.D. will participate in the panel discussion on approaches to treat HBV on Wednesday morning.
Replicor’s nucleic acid polymer (NAP) HBsAg (s-antigen)-release inhibitors therapy blocks s-antigen release and can effectively eliminate s-antigen from the blood (as an example, the serum HBsAg in one patient was reduced from 87,690 to 0.01 IU / ml on treatment, a 6.94 log reduction). Replicor has currently tested its NAP technology in three different human clinical trials in Asia using different treatment modalities: in monotherapy, in combination with short-term immunotherapy and in combination with a complete course of Pegasys™ with the latter regimen resulting in the maintenance of long-term SVR in 80% of patients for greater than 6 months after all treatment is withdrawn.
“Our data suggests that eliminating surface antigen will be a critical part of a multi-step process that will be necessary to achieve a high SVR. Eliminating surface antigen will require a multi-log reduction which our drug has been shown to accomplish in human clinical trials,” said Dr. Vaillant. “We look forward to further validation of NAP activity from additional clinical trials over the next 12 months.”
Replicor is a privately held biopharmaceutical company. For further information about Replicor please visit our website www.replicor.com. Inquires about the company can be directed to email@example.com.